https://mararating.com/report/mrna-1083-mcombriax-for-in-active-immunization-against-influenza-disease-and-covid-19-in-adults-aged-50-years-and-older-as-of-may-2026/
Mrna-1083 / mcombriax for in active immunization against influenza disease and COVID-19 in adults...
Sep 28, 2026 - As of May 2026, MARA's assessment finds MRNA-1083 / mCOMBRIAX's reimbursement risk concentrated in cost effectiveness.
active immunizationinfluenza diseasemrnamcombriaxcovid